• 1. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 2. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 3. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 4. Empowering microfluidics by micro-3D printing and solution-based mineral coating?
  Hongxia Li,Aikifa Raza,Qiaoyu Ge,Jin-You Lu,TieJun Zhang Soft Matter, 2020,16, 6841-6849
• 5. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acids and derivatives Halobenzoic acids and derivatives

Introduction to 3-Bromo-2-chlorobenzamide (CAS No. 1007578-84-8)

3-Bromo-2-chlorobenzamide, with the chemical identifier CAS No. 1007578-84-8, is a significant compound in the realm of pharmaceutical and chemical research. This aromatic amide derivative features a bromine atom at the 3-position and a chlorine atom at the 2-position of a benzene ring, making it a versatile intermediate in synthetic chemistry. The presence of both halogen substituents enhances its reactivity, enabling diverse functionalization pathways that are valuable in drug discovery and material science.

The compound's structure imparts unique electronic and steric properties, making it a candidate for various applications, particularly in medicinal chemistry. Its benzamide core is a common motif in biologically active molecules, often contributing to interactions with biological targets such as enzymes and receptors. The halogen atoms not only facilitate further chemical modifications but also influence the compound's solubility and metabolic stability, critical factors in drug development.

In recent years, 3-Bromo-2-chlorobenzamide has garnered attention for its role in synthesizing novel therapeutic agents. Researchers have leveraged its scaffold to develop compounds with potential applications in oncology, inflammation, and infectious diseases. For instance, studies have explored its derivatives as inhibitors of specific kinases and proteases implicated in cancer progression. The bromine and chlorine atoms serve as handles for palladium-catalyzed cross-coupling reactions, allowing for the introduction of additional functional groups to fine-tune biological activity.

One notable area of research involves the use of 3-Bromo-2-chlorobenzamide in designing small-molecule modulators of bacterial biofilm formation. Biofilms are complex communities of microorganisms that pose significant challenges in clinical settings due to their resistance to antibiotics. By modifying the benzamide core, scientists have identified derivatives that disrupt biofilm matrix components, offering a promising strategy for combating multidrug-resistant pathogens. This work highlights the compound's potential beyond traditional pharmaceutical applications.

The synthesis of 3-Bromo-2-chlorobenzamide typically involves multi-step processes starting from commercially available aromatic precursors. Common methods include halogenation of nitrobenzene derivatives followed by reduction and subsequent amide formation. Advances in green chemistry have also led to more sustainable synthetic routes, employing catalytic methods that minimize waste and improve yields. These innovations align with the broader goal of making drug discovery processes more environmentally friendly.

The pharmacological profile of 3-Bromo-2-chlorobenzamide derivatives continues to be an active field of investigation. Computational modeling techniques have been instrumental in predicting binding affinities and optimizing lead compounds. By integrating experimental data with molecular dynamics simulations, researchers can accelerate the design process, reducing the time required to bring new drugs to market. This interdisciplinary approach underscores the importance of collaboration between chemists, biologists, and computer scientists.

Regulatory considerations also play a crucial role in the development and commercialization of compounds like 3-Bromo-2-chlorobenzamide. Compliance with guidelines from agencies such as the FDA and EMA ensures that therapeutic agents are safe and effective for human use. Manufacturers must adhere to stringent quality control measures throughout production, from raw material sourcing to final product testing. These standards safeguard patient health while fostering innovation in drug development.

The future prospects for 3-Bromo-2-chlorobenzamide are promising, with ongoing research exploring its potential in emerging therapeutic areas. Nanotechnology has opened new avenues for delivering these compounds systemically or targeting specific tissues with high precision. Additionally, combination therapies involving benzamide-based molecules may offer synergistic effects against complex diseases like cancer or neurodegenerative disorders. Such developments reflect the dynamic nature of pharmaceutical research and its ability to adapt to evolving medical needs.

In conclusion, 3-Bromo-2-chlorobenzamide (CAS No. 1007578-84-8) represents a valuable building block in synthetic chemistry with far-reaching implications for drug discovery and material science. Its unique structural features enable diverse modifications, making it a cornerstone for developing novel therapeutic agents. As research continues to uncover new applications and synthetic strategies, this compound is poised to remain at the forefront of scientific innovation.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)